AHA 25: Etripamil in PSVT: Key AHA Insights

10 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
AHA 2025 — In this interview, Dr Narendra Singh (NSC Cardiology, Atlanta, US) reviews the latest AHA data on etripamil, an investigational intranasal, nondihydropyridine calcium channel blocker for the rapid self-termination of paroxysmal supraventricular tachycardia (PSVT).

Dr Singh discusses the burden of PSVT, key findings from randomized and open-label studies, conversion rates with single and repeat dosing, safety and tolerability, and the potential for at-home, patient-administered therapy to reduce emergency department utilization. Dr Singh also addresses considerations around misdiagnosis, hemodynamic effects, and how etripamil could integrate into future PSVT management strategies, including its role alongside ablation.

Interview Questions:
What is etripamil, and what is its therapeutic purpose?
Which clinical studies were included in the AHA analysis?
What were the key safety and efficacy findings?
What side effects were observed in the studies?
How does PSVT impact patients and the healthcare system?
Why is self-administered treatment important in managing PSVT?
What are the current standards of care for PSVT, and what unmet needs remain?

Recorded on-site at AHA 2025.

Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook: https://www.facebook.com/RadcliffeCardiology
Follow us on X: https://x.com/radcliffeCARDIO
Categoria
Cardiology
Commenta per primo questo video.

Prossimo